Insulet Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Ultragenyx Pharmaceutical (RARE)
Insulet Analyst Ratings
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Insulet's Strong Market Position and Financial Health Merit a Buy Rating Despite Legal Challenges
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Barclays Maintains Equal-Weight on Insulet, Lowers Price Target to $200
Insulet Analyst Ratings
Insulet's Strong Financial Performance and Strategic Developments Merit a Buy Rating
Insulet (PODD) Gets a Hold From Stifel Nicolaus
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)
Bank of America Securities Reaffirms Their Buy Rating on Insulet (PODD)
Jefferies Investment Bank: Maintaining the Insulet (PODD.US) rating, adjusted from buy to buy rating, and adjusted the target price from $255.00 to $260.00.
Insulet Analyst Ratings
Jefferies Maintains Buy on Insulet, Raises Price Target to $260
Insulet (PODD) Gets a Buy From Piper Sandler
Stifel Adjusts Price Target on Insulet to $185 From $208
Insulet Corporation: Strong Q1 Performance and Positive Growth Outlook Affirm Buy Rating
Wolfe Research: Upgraded Insulet (PODD.US) rating from Peer Perform to be superior to market rating, target price $200.00.
Insulet Analyst Ratings